Skip to main content
HYPD
NASDAQ Life Sciences

Hyperion DeFi Reports Record Q1 Net Income, Raises FY26 Guidance, and Boosts Cash Reserves

Analysis by Arik Shkolnikov
Sentiment info
Positive
Importance info
9
Price
$3.5
Mkt Cap
$39.871M
52W Low
$1.08
52W High
$17.18
Market data snapshot near publication time

summarizeSummary

Hyperion DeFi reported record Q1 2026 net income and Adjusted EBITDA, significantly raised its full-year guidance, and substantially increased its cash reserves, signaling a strong financial turnaround.


check_boxKey Events

  • Record Q1 2026 Financial Results

    The company reported a net income of $8.8 million and Adjusted EBITDA of $19.5 million for Q1 2026, a significant turnaround from the previous quarter's net loss of ($39.8 million) and Adjusted EBITDA of ($38.9 million).

  • Full-Year 2026 Guidance Raised

    Hyperion DeFi increased its full-year 2026 Adjusted Gross Profit guidance from a range of $4M-$6M to $5M-$7M, reflecting improved operational outlook.

  • Substantial Increase in Cash Reserves

    Cash, cash equivalents, and USDH grew to approximately $16.0 million as of May 11, 2026, up from $9.1 million at the end of Q1 2026 and $6.5 million at the end of Q4 2025.

  • Underwriter Option Exercise

    The company issued 132,249 shares of common stock to Chardan Capital Markets, LLC, generating approximately $0.4 million in net proceeds from the exercise of a 30-day over-allotment option related to a prior offering.


auto_awesomeAnalysis

Hyperion DeFi announced a significant financial turnaround for Q1 2026, reporting record net income of $8.8 million and Adjusted EBITDA of $19.5 million. This marks a dramatic improvement from the previous quarter's substantial losses and follows recent disclosures of digital asset impairment and material weaknesses in internal controls. The company also raised its full-year 2026 Adjusted Gross Profit guidance from $4M-$6M to $5M-$7M, indicating increased confidence in its DeFi operating segments. Furthermore, cash, cash equivalents, and USDH reserves grew to $16.0 million as of May 11, 2026, significantly strengthening its liquidity. The filing also noted the exercise of an underwriter's option, resulting in the issuance of 132,249 shares and approximately $0.4 million in net proceeds, a minor dilutive event compared to the strong financial performance.

At the time of this filing, HYPD was trading at $3.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $39.9M. The 52-week trading range was $1.08 to $17.18. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed HYPD - Latest Insights

HYPD
May 14, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
9
HYPD
May 06, 2026, 4:13 PM EDT
Source: Wiseek News
Importance Score:
8
HYPD
May 06, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
HYPD
May 06, 2026, 4:02 PM EDT
Filing Type: 424B5
Importance Score:
8
HYPD
May 05, 2026, 5:11 PM EDT
Filing Type: DEFA14A
Importance Score:
7
HYPD
May 05, 2026, 5:10 PM EDT
Filing Type: DEF 14A
Importance Score:
7
HYPD
Apr 17, 2026, 4:01 PM EDT
Filing Type: PRE 14A
Importance Score:
8
HYPD
Mar 27, 2026, 5:54 PM EDT
Filing Type: 10-K
Importance Score:
9
HYPD
Mar 26, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
8
HYPD
Mar 24, 2026, 8:53 AM EDT
Source: Reuters
Importance Score:
7